

2 June 2026

Queensland Children's Hospital launches clinical study for paranasal augmentation in patients with unilateral cleft lip

Highlights

- Osteopore and Queensland Children's Hospital (QCH) have launched and commenced a clinical trial for paranasal augmentation in 5 paediatric patients with unilateral (one-sided) cleft lip – which is the augmentation of the nose and surrounding upper jaw structure.
- Patient recruitment for the single-arm feasibility trial is anticipated by June 2027, with patient follow-up expected to continue for 12 months post-surgery.
- The first 3 patients have been recruited to the trial, with the first patient to be treated by July this year.
- Cleft lip and palate affects approximately 1 in 1,000 births globally¹, making it one of the most prevalent congenital conditions worldwide.
- The global cleft lip and palate repair market was valued at approximately USD 1.2b (~AUD 1.7b) in 2024 and is forecast to reach USD 1.9b (~AUD 2.7b) by 2033, growing at a CAGR of 5.5% ².

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the launch of a clinical trial in partnership with Queensland

¹ DOI: 10.15761/OHNS.1000246

² <https://www.verifiedmarketreports.com/product/cleft-lip-and-palate-repair-market/>



Children's Hospital (QCH) to augment the appearance of the nose and surrounding upper jaw structure in children with one-sided cleft lip.

QCH will conduct a single-arm feasibility trial, with the recruitment of up to 5 patients expected by end of 2026. Patient follow-up will continue for 12 months after surgery. The first 3 patients have been recruited to the trial, with the first patient to be treated by July this year.

The trial will be led by Dr. Yun Phua, a Plastic and Reconstructive Surgeon based at QCH and Mater Hospital. This is the second paediatric study led by Dr. Phua – the first study was for the treatment of temporal hollowing, announced on 23 May 2025 ³.

The trial utilises Osteopore's medical-grade polycaprolactone-tricalciumphosphate (mPCL-TCP) scaffolds, manufactured using additive manufacturing (3D printing) to produce patient-specific implants precisely matched to each patient's anatomy.

The scaffolds are 3D printed from a bioresorbable composite (PCL-TCP) that gradually degrades as the body regenerates bone, mimicking the mechanical properties of trabecular bone throughout the healing process. Implants are designed using each patient's CT imaging data and manufactured under Osteopore's established Patient Specific Implant (PSI) workflow, already in clinical use at QCH.

The current standard of care for this condition — cancellous bone grafting harvested from the hip — is associated with poor long-term graft retention and unpredictable outcomes for nasal form.

Osteopore's scaffold is designed to replace this graft entirely, providing a structurally accurate, reproducible alternative that supports bone regeneration and nasal base support without adding surgical time. This represents a meaningful clinical advancement over existing practice.

³ ASX announcement, "OSX partners QCH in trial for temporal hollowing in children", 23 May 2025.



Cleft lip and palate affects approximately 1 in 1,000 births globally⁴, making it one of the most prevalent congenital conditions worldwide. Patients typically undergo multiple reconstructive procedures throughout childhood and adolescence.

The global cleft lip and palate repair market was valued at approximately USD 1.2b (~AUD 1.7b) in 2024 and is forecast to reach USD 1.9b (~AUD 2.7b) by 2033, growing at a CAGR of 5.5%⁵. Growth is being driven by rising surgical volumes, increasing awareness of treatment options, and the adoption of advanced biomaterials and surgical techniques.

This trial, conducted at one of Australia's leading children's hospitals, provides a strong clinical and commercial foundation for broader market adoption.

By delivering a more predictable and durable outcome, this technology has the potential to reduce revision surgeries, improve facial symmetry, and meaningfully enhance quality of life for patients — outcomes being measured using the validated Cleft-Q patient-reported outcome tool.

Commenting on the second study for children at QCH, CEO Dr Yujing Lim said:

"We are delighted to partner with Dr. Phua to advance yet another unique regenerative solution for children. Every child born with a cleft lip deserves the best possible outcome, and this trial reflects our commitment to making that a reality.

"This trial positions us at the forefront of a global market opportunity worth nearly USD 2 billion, and is precisely why we exist as a company — to engineer better outcomes for patients and create lasting value for our shareholders," said Dr Lim.

⁴ DOI: 10.15761/OHNS.1000246

⁵ <https://www.verifiedmarketreports.com/product/cleft-lip-and-palate-repair-market/>



Commenting on the study, Dr. Yun Phua said:

"As a plastic surgeon working with cleft patients, I see firsthand the profound impact facial asymmetry has on a child's confidence and quality of life. The techniques we currently rely on have served us well, but there are still cleft-related facial differences — such as nostril base shape — that remain difficult to correct.

"This trial gives us the opportunity to offer something truly personalised: an implant designed specifically for each child's anatomy that corrects the deformity and, over time, becomes their own tissue. I am excited to lead this work and hopeful it will set a new standard of care for cleft patients", said Dr. Phua

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.



Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

